The proportion of NAFLD in newly diagnosed T2DM patients increased progressively across the Q1-Q4 range of six lipid-lipoprotein ratios, including TG/HDL-C (22.0, 49.4, 58.7 and 75.4%, respectively), TC/HDL-C (30.9, 44.6, 54.0 and 74.0%, respectively), FFA/HDL-C (34.4, 46.8, 57.6 and 66.3%, respectively), LDL-C/HDL-C (35.9, 44.3, 53.6 and 69.0%, respectively), UA/HDL-C (32.8, 45.8, 53.1 and 72.2%, respectively) and APOB/A1 (36.0, 41.8, 55.8 and 71.9%, respectively) (Figure 1). Here, APOB is linked to metabolic dysfunction-associated steatotic liver disease.